
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

GlaxoSmithKline Pharmaceuticals Ltd
Operating Income
GlaxoSmithKline Pharmaceuticals Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
|
Operating Income
â‚ą10.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
![]() |
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
â‚ą67.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
![]() |
Cipla Ltd
NSE:CIPLA
|
Operating Income
â‚ą58.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
![]() |
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
â‚ą122.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
4%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
â‚ą28.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Operating Income
â‚ą21.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
GlaxoSmithKline Pharmaceuticals Ltd
Glance View
GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.

See Also
What is GlaxoSmithKline Pharmaceuticals Ltd's Operating Income?
Operating Income
10.3B
INR
Based on the financial report for Dec 31, 2024, GlaxoSmithKline Pharmaceuticals Ltd's Operating Income amounts to 10.3B INR.
What is GlaxoSmithKline Pharmaceuticals Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
12%
Over the last year, the Operating Income growth was 37%. The average annual Operating Income growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been 20% over the past three years , 12% over the past five years .